ABIVAX Société Anonyme (NASDAQ:ABVX) Receives Average Rating of “Buy” from Analysts

Shares of ABIVAX Société Anonyme (NASDAQ:ABVX) have earned an average recommendation of “Buy” from the seven ratings firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $38.67.

Several research firms have commented on ABVX. Citizens Jmp raised shares of ABIVAX Société Anonyme to a “strong-buy” rating in a report on Wednesday, December 4th. JMP Securities restated a “market outperform” rating and set a $33.00 price target on shares of ABIVAX Société Anonyme in a report on Friday, January 10th.

Institutional Investors Weigh In On ABIVAX Société Anonyme

Institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC purchased a new stake in ABIVAX Société Anonyme during the 4th quarter valued at $29,000. R Squared Ltd purchased a new stake in shares of ABIVAX Société Anonyme in the fourth quarter valued at $36,000. BNP Paribas Financial Markets raised its stake in shares of ABIVAX Société Anonyme by 82.6% in the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock valued at $150,000 after acquiring an additional 5,900 shares during the period. Walleye Capital LLC raised its stake in shares of ABIVAX Société Anonyme by 45.8% in the third quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock valued at $2,965,000 after acquiring an additional 80,807 shares during the period. Finally, abrdn plc raised its stake in shares of ABIVAX Société Anonyme by 167.7% in the third quarter. abrdn plc now owns 316,431 shares of the company’s stock valued at $3,645,000 after acquiring an additional 198,225 shares during the period. 47.91% of the stock is owned by institutional investors.

ABIVAX Société Anonyme Price Performance

ABVX stock opened at $5.87 on Thursday. The company’s fifty day moving average price is $7.40 and its 200-day moving average price is $9.80. ABIVAX Société Anonyme has a one year low of $5.49 and a one year high of $17.02.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.